A BILL 
To amend the Public Health Service Act to give the United 
States Preventive Services Task Force the authority to 
take early action based on scientific evidence, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Preventive Services 
4
Early Action Act’’. 
5
01:55 Nov 22, 2022
H9310
2 
•HR 9310 IH
SEC. 2. CHANGES TO UNITED STATES PREVENTIVE SERV-
1
ICES TASK FORCE. 
2
Section 915(a) of the Public Health Service Act (42 
3
U.S.C. 299b–4(a)) is amended— 
4
(1) in paragraph (2)— 
5
(A) in subparagraph (E), by striking 
6
‘‘and’’ at the end; 
7
(B) in subparagraph (F), by striking the 
8
period at the end and inserting ‘‘; and’’; and 
9
(C) by adding at the end the following: 
10
‘‘(G) the publication of quarterly reports 
11
on the Task Force’s website identifying— 
12
‘‘(i) a list of clinical preventive rec-
13
ommendations of the Task Force with re-
14
spect to the scientific information de-
15
scribed in paragraph (4)(B); and 
16
‘‘(ii) a list of topics that the Scientific 
17
Director determines are appropriate for 
18
early action as described in paragraph 
19
(5).’’; 
20
(2) by redesignating paragraphs (4), (5), (6), 
21
and (7) as paragraphs (7), (8), (9), and (11), re-
22
spectively; 
23
(3) after making such redesignations, by insert-
24
ing after paragraph (3) the following: 
25
01:55 Nov 22, 2022
H9310
3 
•HR 9310 IH
‘‘(4) ONGOING
REVIEW
OF
SCIENTIFIC
EVI-
1
DENCE AND REQUESTS FOR EARLY ACTION.—For 
2
the purpose described in paragraph (1), the Task 
3
Force shall establish and implement a process for 
4
the ongoing review of scientific evidence related to 
5
updating previous clinical preventive recommenda-
6
tions of the Task Force under paragraph (5) and re-
7
viewing new topics for the development of rec-
8
ommendations for the health care community. Such 
9
scientific evidence shall include— 
10
‘‘(A) information from sources audited 
11
under the LitWatch process described in Ap-
12
pendix III of the United States Preventive 
13
Services Task Force Procedure Manual (or any 
14
successor to such process); and 
15
‘‘(B) information submitted through a pub-
16
lic submission process, which may include evi-
17
dence— 
18
‘‘(i) of the impact of clinical preven-
19
tive services on populations or age groups 
20
for which such clinical preventive services 
21
do not have in effect a rating of A or B; 
22
‘‘(ii) to fill research gaps identified by 
23
the Task Force; 
24
01:55 Nov 22, 2022
H9310
4 
•HR 9310 IH
‘‘(iii) of a new, novel screening modal-
1
ity or technology, preventive medication, or 
2
other preventive service not previously re-
3
viewed by the Task Force; 
4
‘‘(iv) of health outcomes from a clin-
5
ical preventive service that was previously 
6
considered but not recommended by the 
7
Task Force; or 
8
‘‘(v) changes in the public health im-
9
pact of a specific condition, whether in 
10
general or as such changes relate to a spe-
11
cific population. 
12
‘‘(5) EARLY ACTION BASED ON SCIENTIFIC EVI-
13
DENCE.— 
14
‘‘(A) DETERMINATION BY SCIENTIFIC DI-
15
RECTOR.—Not less than once per quarter, the 
16
Scientific Director shall determine whether the 
17
scientific evidence reviewed under paragraph (4) 
18
supports— 
19
‘‘(i) early review of a previous clinical 
20
preventive recommendation of the Task 
21
Force before the previous recommendation 
22
is subject to full review under the 5-year 
23
review period described in paragraph (2); 
24
or 
25
01:55 Nov 22, 2022
H9310
5 
•HR 9310 IH
‘‘(ii) modification of a previous clinical 
1
preventive recommendation of the Task 
2
Force or any portion thereof before the 
3
previous recommendation is subject to full 
4
review under the 5-year review period de-
5
scribed in paragraph (2). 
6
‘‘(B) CONSIDERATIONS.—In making a de-
7
termination under subparagraph (A), the Sci-
8
entific Director shall take into consideration 
9
whether the scientific evidence involved— 
10
‘‘(i) includes information on a new or 
11
novel intervention, modality, technology, 
12
population, or strategy not previously con-
13
sidered by the Task Force in the develop-
14
ment of the previous clinical preventive 
15
recommendation; 
16
‘‘(ii) helps to address a research gap 
17
identified by the Task Force when devel-
18
oping the previous recommendation; 
19
‘‘(iii) relates to a previous rec-
20
ommendation for a preventive service or 
21
treatment of a disease or condition with a 
22
high impact on public health or with dis-
23
parities in screening rates, incidence, or 
24
01:55 Nov 22, 2022
H9310
6 
•HR 9310 IH
health outcomes linked to socioeconomic 
1
status or race; 
2
‘‘(iv) is based on the development of 
3
new technologies or modalities that would 
4
allow for easier disease detection or in-
5
crease utilization of recommended clinical 
6
preventative services; or 
7
‘‘(v) 
is 
supported 
by 
additional 
8
sources of data for any subpopulations (in-
9
cluding subpopulations based on gender, 
10
race, ethnicity, genetic predisposition, so-
11
cioeconomic status, geographic location, or 
12
other risk factors) not considered in the 
13
previous recommendation. 
14
‘‘(C) RESPONSE BY TASK FORCE.—If the 
15
Scientific Director of the Task Force deter-
16
mines under subparagraph (A) that the sci-
17
entific evidence supports the need for early ac-
18
tion, the Task Force shall— 
19
‘‘(i) review the scientific evidence in 
20
support of the determination at the next 
21
meeting of the Task Force, which shall be 
22
held not later than 3 months after the Sci-
23
entific Director’s determination; and 
24
‘‘(ii) determine that— 
25
01:55 Nov 22, 2022
H9310
7 
•HR 9310 IH
‘‘(I) the scientific evidence does 
1
not support the need for early action; 
2
‘‘(II) the scientific evidence sup-
3
ports the need for an early review of 
4
a previous clinical preventive rec-
5
ommendation before the previous rec-
6
ommendation is subject to full review 
7
under the 5-year review period de-
8
scribed in paragraph (2); or 
9
‘‘(III) the scientific evidence sup-
10
ports the need to modify a previous 
11
clinical preventive recommendation or 
12
any portion thereof before the pre-
13
vious recommendation is subject to 
14
full review under the 5-year review pe-
15
riod described in paragraph (2), which 
16
may include recommending a new 
17
clinical preventive service, screening 
18
test, or preventive medication without 
19
reviewing or modifying the eligible 
20
population 
in 
the 
previous 
rec-
21
ommendation. 
22
‘‘(D) EARLY ACTION.—If the Task Force 
23
determines that the scientific evidence supports 
24
the need for an early review of a previous clin-
25
01:55 Nov 22, 2022
H9310
8 
•HR 9310 IH
ical preventive recommendation, as described in 
1
subparagraph 
(C)(ii)(II), 
the 
Task 
Force 
2
shall— 
3
‘‘(i) allow for public comment on a 
4
draft recommendation; and 
5
‘‘(ii) not later than 6 months after 
6
such determination, conclude such early re-
7
view and make a final recommendation. 
8
‘‘(E) MODIFICATION.—If the Task Force 
9
determines that the scientific evidence supports 
10
the need to modify a previous clinical preventive 
11
recommendation or any portion thereof, as de-
12
scribed in subparagraph (C)(ii)(III), the Task 
13
Force shall finalize the modified recommenda-
14
tion not later than 90 days after such deter-
15
mination. Any modification approved under this 
16
subparagraph shall be in effect until the next 
17
review of such recommendation under the 5- 
18
year review period described in paragraph (2). 
19
‘‘(6) APPROVAL
OF
CLEARANCE
OF
CERTAIN 
20
PRODUCTS.—Not later than 3 months after the ap-
21
proval or clearance by the Food and Drug Adminis-
22
tration of a screening test or preventive medication 
23
that is a preventive strategy or modality pertaining 
24
to but not included in a previous clinical preventive 
25
01:55 Nov 22, 2022
H9310
9 
•HR 9310 IH
recommendation of the Task Force, the Task Force 
1
shall determine that the approval or clearance of the 
2
product— 
3
‘‘(A) does not support the need for early 
4
action; 
5
‘‘(B) supports the need for an early review 
6
of a previous clinical preventive recommenda-
7
tion before the previous recommendation is sub-
8
ject to full review under the 5-year review pe-
9
riod described in paragraph (2); or 
10
‘‘(C) supports the need to modify a pre-
11
vious clinical preventive recommendation or any 
12
portion 
thereof 
before 
the 
previous 
rec-
13
ommendation is subject to full review under the 
14
5-year review period described in paragraph (2), 
15
which may include recommending a new clinical 
16
preventive service, screening test, or preventive 
17
medication without reviewing or modifying the 
18
eligible population in the previous recommenda-
19
tion.’’; 
20
(4) by inserting after paragraph (9), as so re-
21
designated, the following: 
22
‘‘(10) DEFINITIONS.—In this section: 
23
‘‘(A) The term ‘public submission process’ 
24
means an online mechanism that allows any 
25
01:55 Nov 22, 2022
H9310
10 
•HR 9310 IH
member of the general public to submit sci-
1
entific evidence for review by the Scientific Di-
2
rector and the Task Force staff. 
3
‘‘(B) The term ‘Scientific Director’ means 
4
the chief physician, researcher, and technical 
5
advisor for the Task Force, as determined by 
6
the Director.’’; and 
7
(5) by amending paragraph (11), as so redesig-
8
nated, to read as follows: 
9
‘‘(11) AUTHORIZATION OF APPROPRIATIONS.— 
10
There are authorized to be appropriated such sums 
11
as may be necessary for each fiscal year to carry out 
12
the activities of the Task Force, of which such sums 
13
as may be necessary are authorized to be appro-
14
priated for fiscal years 2023 and 2024 to hire addi-
15
tional staff to carry out paragraphs (4) and (5).’’. 
16
Æ 
01:55 Nov 22, 2022
H9310
